{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:19:42Z","timestamp":1794694782493,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.metabol.2025.156463","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:05:44Z","timestamp":1764781544000},"page":"156463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"175","author":[{"given":"Paschalis","family":"Karakasis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Vlachos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios P.","family":"Antoniadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Siontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2025.156463_bb0005","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","author":"Joglar","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2025.156463_bb0010","article-title":"Correction to: 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the Europe","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2025.156463_bb0015","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz","year":"2024","journal-title":"Lancet Reg Heal Eur"},{"key":"10.1016\/j.metabol.2025.156463_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaf026","article-title":"The evolving epidemiological landscape of atrial fibrillation: trends, challenges, and opportunities for improved patient care","volume":"27","author":"Zuin","year":"2025","journal-title":"Europace"},{"key":"10.1016\/j.metabol.2025.156463_bb0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.metabol.2025.156463_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032277","article-title":"Impact of obesity on atrial fibrillation pathogenesis and treatment options","volume":"13","author":"Sha","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2025.156463_bb0035","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","article-title":"Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise","volume":"70","author":"Lavie","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0040","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)","volume":"65","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0055","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0060","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156463_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156463_bb0075","article-title":"Deep learning-enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis","author":"Barrado-Ballestero","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2025.156463_bb0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156463_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like Peptide-1) receptor mediates cardiovascular protection by Liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2025.156463_bb0090","first-page":"3669","article-title":"Exendin-4 inhibits atrial arrhythmogenesis in a model of myocardial infarction-induced heart failure via the GLP-1 receptor signaling pathway","volume":"20","author":"Chen","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0095","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00380-018-01327-4","article-title":"Liraglutide suppresses atrial electrophysiological changes","volume":"34","author":"Nakamura","year":"2019","journal-title":"Heart Vessel"},{"key":"10.1016\/j.metabol.2025.156463_bb0100","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","article-title":"Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice","volume":"8","author":"Bohne","year":"2023","journal-title":"JACC Basic to Transl Sci"},{"key":"10.1016\/j.metabol.2025.156463_bb0105","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training n.d. https:\/\/training.cochrane.org\/handbook\/current (accessed January 17, 2023)."},{"key":"10.1016\/j.metabol.2025.156463_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2025.156463_bb0115","author":"Haddaway","year":"2021","journal-title":"Citationchaser: an R package and Shiny app for forward and backward citations chasing in academic searching"},{"key":"10.1016\/j.metabol.2025.156463_bb0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1145\/2110363.2110464","article-title":"Deploying an interactive machine learning system in an Evidence-based Practice Center: Abstrackr","author":"Wallace","year":"2012","journal-title":"IHI\u201912 - Proc 2nd ACM SIGHIT Int Heal Informatics Symp"},{"key":"10.1016\/j.metabol.2025.156463_bb0125","first-page":"366","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2025.156463_bb0130","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses | Cochrane Training n.d. https:\/\/training.cochrane.org\/handbook\/current\/chapter-10#section-10-10 (accessed January 8, 2024)."},{"key":"10.1016\/j.metabol.2025.156463_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2025.156463_bb0140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist Retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0145","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156463_bb0150","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2025.156463_bb0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2025.156463_bb0160","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.metabol.2025.156463_bb0165","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156463_bb0170","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of Liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2025.156463_bb0175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0180","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.metabol.2025.156463_bb0185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.metabol.2025.156463_bb0190","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0195","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.metabol.2025.156463_bb0200","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0210","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.16005","article-title":"Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging, phase 2, randomized, placebo-controlled study","volume":"27","author":"Amin","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2025.156463_bb0220","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2025.156463_bb0225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2025.156463_bb0230","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0235","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: The SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156463_bb0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156463_bb0245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13098-025-01712-w","article-title":"Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: casual evidence from a drug target Mendelian randomization","volume":"17","author":"Zhang","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2025.156463_bb0250","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s11606-023-08589-3","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study","volume":"39","author":"Xu","year":"2024","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0255","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-025-00751-y","article-title":"Association of glucagon-like peptide-1 receptor agonist with incident atrial fibrillation","author":"Khalil","year":"2025","journal-title":"Am J Cardiovasc Drugs Drugs, Devices, Other Interv"},{"key":"10.1016\/j.metabol.2025.156463_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01549-x","article-title":"The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156463_bb0265","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.125.014069","article-title":"Effect of semaglutide on atrial arrhythmias recurrence following ablation for atrial fibrillation: a prospective study","author":"Guo","year":"2025","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0270","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/jce.16737","article-title":"Long-term impact of GLP-1 receptor agonists on AF recurrence after ablation in obese patients","volume":"36","author":"Patel","year":"2025","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacep.2024.03.031","article-title":"Effects of glucagon-like Peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation","author":"Satti","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0280","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jacc.2020.07.017","article-title":"Epicardial adipose tissue accumulation confers atrial conduction abnormality","volume":"76","author":"Nalliah","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0285","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2025.156463_bb0290","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvz042","article-title":"Effects of Semaglutide versus Dulaglutide on Epicardial fat thickness in subjects with type 2 diabetes and obesity","volume":"4","author":"Iacobellis","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.metabol.2025.156463_bb0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and Paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacbts.2025.101349","article-title":"Effect of Semaglutide on Epicardial Adipogenesis and hiPSC-atrial cardiomyocytes new Hope in targeting Epicardial adipose tissue","volume":"10","author":"Gaborit","year":"2025","journal-title":"JACC Basic to Transl Sci"},{"key":"10.1016\/j.metabol.2025.156463_bb0305","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-024-02342-8","article-title":"Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia\/reperfusion through modulating macrophages polarization","volume":"23","author":"Zhao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156463_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109224","article-title":"Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1","volume":"118","author":"Zhao","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2025.156463_bb0315","article-title":"Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?","volume":"27","author":"Zhang","year":"2025","journal-title":"Eur Eur pacing, arrhythmias, card Electrophysiol J work groups card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0320","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10561-022-10021-9","article-title":"Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21\/PTEN\/PI3K pathway","volume":"24","author":"Wang","year":"2023","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.metabol.2025.156463_bb0325","article-title":"Liraglutide improves antioxidant defense in hearts of spontaneously hypertensive female rats independently of changes in blood pressure in a pre-clinical model of menopause","volume":"58","author":"Santos","year":"2025","journal-title":"Brazilian J Med Biol Res = Rev Bras Pesqui Medicas e Biol"},{"key":"10.1016\/j.metabol.2025.156463_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00202","article-title":"Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart","volume":"10","author":"Ding","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2025.156463_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107294","article-title":"Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels","volume":"300","author":"Zhou","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2025.156463_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49364-x","article-title":"Central glucagon-like Peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats","volume":"9","author":"Katsurada","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156463_bb0345","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of Semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0350","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2025.156463_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156463_bb0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.diabres.2016.04.046","article-title":"Improved diastolic function in type 2 diabetes after a six month liraglutide treatment","volume":"118","author":"Saponaro","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2025.156463_bb0365","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/jmri.27009","article-title":"Effect of liraglutide on cardiovascular function and myocardial tissue characteristics in type 2 diabetes patients of south Asian descent living in the Netherlands: a double-blind, randomized, placebo-controlled trial","volume":"51","author":"Paiman","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.metabol.2025.156463_bb0370","first-page":"1929","article-title":"PREVention and regReSsive effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study","volume":"20","author":"Middeldorp","year":"2018","journal-title":"Eur Eur Pacing, Arrhythmias, Card Electrophysiol J Work Groups Card Pacing, Arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0375","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","article-title":"Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study","volume":"64","author":"Pathak","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2025.156463_bb0380","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf784.4243","article-title":"Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial","volume":"46","author":"Plutzky","year":"2025","journal-title":"Eur Heart J"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:22:28Z","timestamp":1781065348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525003324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":76,"alternative-id":["S0026049525003324"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156463","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156463"}}